Septerna (NASDAQ:SEPN) Trading Down 5.3% - Here's What Happened

Key Points

• Septerna, Inc. (NASDAQ: SEPN) shares declined by 5.3% to a last traded price of $22.81, significantly below its previous close of $24.09, with trading volume dropping to 76,664 shares.
• Equities analysts have mixed ratings on the stock, with a consensus price target of $26.75 and varying assessments ranging from "buy" to "sell."
• The company reported a substantial earnings miss, with a quarterly EPS of ($0.56), far below expectations of ($0.05), alongside revenues of only $0.12 million compared to analyst estimates of $22.50 million.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares fell 5.3% on Tuesday . The stock traded as low as $22.80 and last traded at $22.81. 76,664 shares were traded during trading, a decline of 87% from the average session volume of 606,051 shares. The stock had previously closed at $24.09.

Wall Street Analyst Weigh In

Several equities analysts have commented on SEPN shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of Septerna in a report on Friday, September 5th. HC Wainwright restated a "buy" rating and set a $26.00 target price on shares of Septerna in a research note on Thursday, August 21st. Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Septerna from a "sell" rating to a "hold" rating in a report on Sunday, September 21st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Septerna currently has an average rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Stock Performance

The business's fifty day moving average is $15.07 and its 200-day moving average is $11.26. The firm has a market cap of $1.04 billion and a P/E ratio of -2.31.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BVF Inc. IL lifted its holdings in Septerna by 79.3% in the first quarter. BVF Inc. IL now owns 4,396,124 shares of the company's stock valued at $25,454,000 after buying an additional 1,944,100 shares during the period. TRV GP VI LLC grew its stake in Septerna by 33.6% during the first quarter. TRV GP VI LLC now owns 4,211,659 shares of the company's stock worth $24,386,000 after purchasing an additional 1,059,203 shares during the period. Checkpoint Capital L.P. bought a new position in shares of Septerna during the 1st quarter worth approximately $4,776,000. ADAR1 Capital Management LLC bought a new position in shares of Septerna during the 1st quarter worth approximately $4,174,000. Finally, Perceptive Advisors LLC bought a new position in shares of Septerna during the 2nd quarter worth approximately $5,723,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.